These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. The HIV-1 protease as a therapeutic target for AIDS. Debouck C AIDS Res Hum Retroviruses; 1992 Feb; 8(2):153-64. PubMed ID: 1540403 [TBL] [Abstract][Full Text] [Related]
46. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands. Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624 [TBL] [Abstract][Full Text] [Related]
47. Comparison of the molecular dynamics and calculated binding free energies for nine FDA-approved HIV-1 PR drugs against subtype B and C-SA HIV PR. Ahmed SM; Kruger HG; Govender T; Maguire GE; Sayed Y; Ibrahim MA; Naicker P; Soliman ME Chem Biol Drug Des; 2013 Feb; 81(2):208-18. PubMed ID: 23017010 [TBL] [Abstract][Full Text] [Related]
48. X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease. Jhoti H; Singh OM; Weir MP; Cooke R; Murray-Rust P; Wonacott A Biochemistry; 1994 Jul; 33(28):8417-27. PubMed ID: 8031777 [TBL] [Abstract][Full Text] [Related]
49. Constructing Interconsistent, Reasonable, and Predictive Models for Both the Kinetic and Thermodynamic Properties of HIV-1 Protease Inhibitors. Qu S; Huang S; Pan X; Yang L; Mei H J Chem Inf Model; 2016 Oct; 56(10):2061-2068. PubMed ID: 27624663 [TBL] [Abstract][Full Text] [Related]
50. Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic. Kiso Y Adv Exp Med Biol; 1995; 362():413-23. PubMed ID: 8540352 [No Abstract] [Full Text] [Related]
51. Targeting HIV-1 protease: a test of drug-design methodologies. West ML; Fairlie DP Trends Pharmacol Sci; 1995 Feb; 16(2):67-75. PubMed ID: 7762084 [TBL] [Abstract][Full Text] [Related]
52. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714 [TBL] [Abstract][Full Text] [Related]
53. Active site binding modes of curcumin in HIV-1 protease and integrase. Vajragupta O; Boonchoong P; Morris GM; Olson AJ Bioorg Med Chem Lett; 2005 Jul; 15(14):3364-8. PubMed ID: 15950462 [TBL] [Abstract][Full Text] [Related]
54. Design and synthesis of HIV protease inhibitors. Variations of the carboxy terminus of the HIV protease inhibitor L-682,679. deSolms SJ; Giuliani EA; Guare JP; Vacca JP; Sanders WM; Graham SL; Wiggins JM; Darke PL; Sigal IS; Zugay JA J Med Chem; 1991 Sep; 34(9):2852-7. PubMed ID: 1910089 [TBL] [Abstract][Full Text] [Related]
55. Probing structure-function relationships in human immunodeficiency virus type 1 protease via molecular dynamics simulation. Harte WE; Beveridge DL Methods Enzymol; 1994; 241():178-95. PubMed ID: 7854178 [TBL] [Abstract][Full Text] [Related]
56. Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir. Chen X; Weber IT; Harrison RW J Mol Model; 2004 Dec; 10(5-6):373-81. PubMed ID: 15597206 [TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation. Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016 [TBL] [Abstract][Full Text] [Related]
58. Mining HIV protease cleavage data using genetic programming with a sum-product function. Yang ZR; Dalby AR; Qiu J Bioinformatics; 2004 Dec; 20(18):3398-405. PubMed ID: 15256407 [TBL] [Abstract][Full Text] [Related]
59. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme. Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826 [TBL] [Abstract][Full Text] [Related]
60. Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application. Kesteleyn B; Amssoms K; Schepens W; Hache G; Verschueren W; Van De Vreken W; Rombauts K; Meurs G; Sterkens P; Stoops B; Baert L; Austin N; Wegner J; Masungi C; Dierynck I; Lundgren S; Jönsson D; Parkes K; Kalayanov G; Wallberg H; Rosenquist A; Samuelsson B; Van Emelen K; Thuring JW Bioorg Med Chem Lett; 2013 Jan; 23(1):310-7. PubMed ID: 23177258 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]